The effect of food on the pharmacokinetics, tolerability and pharmacodynamics of BNC210 in healthy male volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs BNC 210 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 08 Jul 2011 Actual initiation date (5 May 2010) added as reported by Australian New Zealand Clinical Trials Registry.
- 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12610000442000).
- 21 Jun 2010 Status changed from planning to completed, according to a Bionomics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History